Onlookers may have had their doubts about the setup between Avalon Ventures and Glaxosmithkline plc (GSK) that led to last November's launch of Sitari Pharmaceuticals Inc. by way of $10 million in series A cash with a buyout option for GSK, and brought a promise of as many as 10 companies to be established the same way.